长链非编码RNA牛磺酸上调基因1与冠状动脉支架内再狭窄的相关性

高小燕, 张韶辉, 魏广和. 长链非编码RNA牛磺酸上调基因1与冠状动脉支架内再狭窄的相关性[J]. 临床心血管病杂志, 2022, 38(1): 39-43. doi: 10.13201/j.issn.1001-1439.2022.01.008
引用本文: 高小燕, 张韶辉, 魏广和. 长链非编码RNA牛磺酸上调基因1与冠状动脉支架内再狭窄的相关性[J]. 临床心血管病杂志, 2022, 38(1): 39-43. doi: 10.13201/j.issn.1001-1439.2022.01.008
GAO Xiaoyan, ZHANG Shaohui, WEI Guanghe. Correlation between long non-coding RNA taurine up-regulated gene 1 and coronary in-stent restenosis[J]. J Clin Cardiol, 2022, 38(1): 39-43. doi: 10.13201/j.issn.1001-1439.2022.01.008
Citation: GAO Xiaoyan, ZHANG Shaohui, WEI Guanghe. Correlation between long non-coding RNA taurine up-regulated gene 1 and coronary in-stent restenosis[J]. J Clin Cardiol, 2022, 38(1): 39-43. doi: 10.13201/j.issn.1001-1439.2022.01.008

长链非编码RNA牛磺酸上调基因1与冠状动脉支架内再狭窄的相关性

  • 基金项目:
    山东省医药卫生科技发展计划项目(No:2019WS367)
详细信息

Correlation between long non-coding RNA taurine up-regulated gene 1 and coronary in-stent restenosis

More Information
  • 目的 探讨长链非编码RNA(LncRNA)牛磺酸上调基因1(TUG1)在冠状动脉(冠脉)支架内再狭窄(ISR)患者外周血中的表达水平,研究TUG1对支架内再狭窄的诊断价值。方法 选取2019年5月—2021年6月于济宁医学院附属医院心内科住院且既往置入过冠脉支架的患者,入院复查冠脉造影评估冠脉支架是否狭窄,根据冠脉造影结果分为支架内再狭窄(ISR)组(26例)和支架内非狭窄(N-ISR)组(26例)。首先收集患者外周血,用单核细胞分离液提取单核细胞,从上述细胞中提取RNA,然后采用实时荧光定量聚合酶链式反应(qRT-PCR)法检测LncRNA TUG1表达水平;采用多因素logistic回归分析研究ISR患者的独立危险因素,采用受试者工作特征曲线(ROC曲线)来评估TUG1对ISR的诊断价值。结果 ISR组TUG1表达量高于N-ISR组[(0.1982±0.2276)∶(0.0704±0.0869),P< 0.05],差异有统计学意义。多因素logistic回归分析表明,TUG1为ISR的独立危险因素(OR=1.934,95%CI1.017~3.677,P=0.044)。TUG1的ROC曲线下面积为0.703,灵敏度为65.4%,特异度为73.1%。结论 ISR组患者TUG1的表达水平增高。高表达的TUG1是ISR的独立危险因素,TUG1可能是预测经皮冠脉介入治疗术后发生ISR的新型生物标志物。
  • 加载中
  • 图 1  ISR组与N-ISR组TUG1表达水平

    Figure 1.  TUG1 expression in ISR and N-ISR group

    图 2  ROC曲线

    Figure 2.  ROC curve

    表 1  基线资料比较

    Table 1.  General data 例(%), X±S

    基线变量 ISR组(26例) N-ISR组(26例) t2 P
    男性/例(%) 19(73.1) 13(50.0) 2.925 0.087
    年龄/岁 63.31±11.40 63.96±10.39 -0.216 0.830
    收缩压/mmHg 133.96±20.37 134.35±18.59 -0.071 0.940
    舒张压/mmHg 76.38±9.782 79.96±10.91 -1.245 0.220
    BMI/(kg·m-2) 26.17±3.25 26.24±3.38 -0.76 0.940
    吸烟史/例(%) 17(65.4) 7(26.9) 7.738 0.005
    糖尿病/例(%) 15(57.7) 6(23.1) 6.47 0.011
    饮酒史/例(%) 10(38.5) 9(34.6) 0.083 0.773
    高血压病/例(%) 18(69.2) 17(65.4) 0.087 0.768
    TG/(mmol·L-1) 1.32±0.49 1.39±0.64 -0.39 0.700
    TC/(mmol·L-1) 3.56±0.98 3.90±0.98 -1.227 0.230
    LDL-C/(mmol·L-1) 2.12±0.80 2.25±0.79 -0.579 0.570
    HDL-C/(mmol·L-1) 1.13±0.28 1.35±0.36 -2.505 0.020
    脂蛋白a/(mg·L-1) 348.73±373.68 451.12±404.59 -0.948 0.350
    尿素/(mmol·L-1) 5.13±1.75 5.29±1.67 -0.34 0.740
    肌酐/(μmol·L-1) 67.26±12.31 69.30±15.61 -0.524 0.600
    ALT/(U·L-1) 22.86±12.79 27.87±28.02 -0.829 0.410
    AST/(U·L-1) 22.73±14.17 23.46±11.95 -0.2 0.840
    WBC/(×109·L-1) 7.04±1.59 7.47±2.42 -0.757 0.450
    HB/(g·L-1) 135.96±16.41 136.69±16.83 -0.159 0.880
    PLT/(×109·L-1) 244.81±69.69 247.69±54.77 -0.166 0.870
    D-二聚体/(mg·L-1) 0.32±0.15 0.51±0.28 -2.998 0.005
    肌酸激酶/(U·L-1) 113.38±95.52 115.81±61.41 -0.109 0.914
    LVEF/% 57.81±6.35 59.19±2.50 -1.035 0.308
    CK-MB/(ng·mL-1) 5.67±9.03 5.66±13.21 0.003 0.997
    乳酸脱氢酶/(U·L-1) 221.31±185.98 187.85±22.40 0.911 0.371
    a-羟丁酸脱氢酶/(U·L-1) 179.19±170.00 151.00±19.00 0.84 0.408
    下载: 导出CSV

    表 2  多因素Logistic回归分析结果

    Table 2.  Logistic analysis

    变量 β Wald χ2 OR 95%CI P
    吸烟 1.435 4.296 4.200 1.081~16.316 0.038
    糖尿病 1.835 6.509 6.267 1.530~25.666 0.011
    TUG1 6.593 4.044 1.934 1.017~3.677 0.044
    下载: 导出CSV
  • [1]

    Bradley SM, Borgerding JA, Wood GB, et al. Incidence, risk factors, and outcomes associated with in-hospital acute myocardial infarction[J]. JAMA Netw Open, 2019, 2(1): e187348. doi: 10.1001/jamanetworkopen.2018.7348

    [2]

    Severino P, D'Amato A, Pucci M, et al. Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction[J]. Int J Mol Sci, 2020, 21(21): 111.

    [3]

    Jian W, Li L, Wei XM, et al. Prognostic value of angiopoietin-2 for patients with coronary heart disease after elective PCI[J]. Medicine(Baltimore), 2019, 98(5): e14216.

    [4]

    Aoki J, Tanabe K. Mechanisms of drug-eluting stent restenosis[J]. Cardiovasc Interv Ther, 2021, 36(1): 23-29. doi: 10.1007/s12928-020-00734-7

    [5]

    Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review[J]. J Geriatr Cardiol, 2018, 15(2): 173-184.

    [6]

    王尚, 刘源, 郑璐, 等. 总胆红素、纤维蛋白原/白蛋白比值及二者联合检测预测PCI术后支架内再狭窄的价值[J]. 临床心血管病杂志, 2021, 37(8): 714-719. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202108007.htm

    [7]

    Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs[J]. Cell, 2018, 172(3): 393-407. doi: 10.1016/j.cell.2018.01.011

    [8]

    Zhang S, Li L, Wang J, et al. Recent advances in the regulation of ABCA1 and ABCG1 by lncRNAs[J]. Clin Chim Acta, 2021, 516: 100-110. doi: 10.1016/j.cca.2021.01.019

    [9]

    Wang S, Cao W, Gao S, et al. TUG1 regulates pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension[J]. Can J Cardiol, 2019, 35(11): 1534-1545. doi: 10.1016/j.cjca.2019.07.630

    [10]

    Dorje T, Zhao G, Scheer A, et al. SMARTphone and social media-based Cardiac Rehabilitation and Secondary Prevention(SMART-CR/SP)for patients with coronary heart disease in China: a randomised controlled trial protocol[J]. BMJ Open, 2018, 8(6): e021908. doi: 10.1136/bmjopen-2018-021908

    [11]

    Wang Z, Liu C, Fang H. Blood cell parameters and predicting coronary in-stent restenosis[J]. Angiology, 2019, 70(8): 711-718. doi: 10.1177/0003319719830495

    [12]

    Lundy EF, Shlofmitz ES, Jeremias A, et al. Intraoperative optical coherence tomography of the saphenous vein conduit in patients undergoing coronary artery bypass surgery[J]. Circ Cardiovasc Interv, 2021, 14(10): e011109.

    [13]

    Correction to: restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J]. Circ Cardiovasc Interv, 2019, 12(10): e000044.

    [14]

    Statello L, Guo CJ, Chen LL, et al. Author correction: gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 159.

    [15]

    Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases[J]. J Cell Mol Med, 2018, 22(12): 5768-5775. doi: 10.1111/jcmm.13866

    [16]

    付楚涵, 陈敏, 胡双海, 等. 牛磺酸上调基因1与疾病的关系[J]. 中南大学学报(医学版), 2020, 45(9): 1127-1135. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202009021.htm

    [17]

    Li FP, Lin DQ, Gao LY. LncRNA TUG1 promotes proliferation of vascular smooth muscle cell and atherosclerosis through regulating miRNA-21/PTEN axis[J]. Eur Rev Med Pharmacol Sci, 2018, 22(21): 7439-7447.

    [18]

    Yan HY, Bu SZ, Zhou WB, et al. TUG1 promotes diabetic atherosclerosis by regulating proliferation of endothelial cells via Wnt pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(20): 6922-6929.

    [19]

    Redfors B, Généreux P, Witzenbichler B, et al. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study[J]. Am Heart J, 2018, 197: 142-149. doi: 10.1016/j.ahj.2017.11.011

    [20]

    Omeh DJ, Shlofmitz E. Restenosis. In: StatPearls. Treasure Island(FL): StatPearls Publishing; August 11, 2021.

    [21]

    Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome[J]. Circulation, 1999, 100(18): 1872-1878. doi: 10.1161/01.CIR.100.18.1872

    [22]

    尹亮, 甘露, 史博群, 等. 长链非编码RNA在冠状动脉慢性完全闭塞病变的应用展望[J]. 临床心血管病杂志, 2021, 37(2): 172-177. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202102017.htm

  • 加载中

(2)

(2)

计量
  • 文章访问数:  1628
  • PDF下载数:  356
  • 施引文献:  0
出版历程
收稿日期:  2021-07-11
刊出日期:  2022-01-13

目录